Updated:
AI Life Sciences Investments
AI Life Sciences Investments is a single-family office with a concentrated thesis: backing companies that deploy artificial intelligence to compress...
AI Life Sciences Investments
AI Life Sciences Investments is a single-family office with a concentrated thesis: backing companies that deploy artificial intelligence to compress timelines and reduce costs in drug development and clinical care. The firm's presence across four US cities — New York, St. Louis, Chicago, and Elgin — points to a distributed investment operation, likely reflecting the geographic roots of its founding family. The investment strategy centers on early-stage ventures at the convergence of machine learning and biology. Targeted subsectors include generative AI for protein design, machine learning-enabled diagnostics, and clinical workflow automation. The firm is known to participate in seed and Series A rounds, typically as a co-investor alongside specialist healthcare VCs. While specific portfolio holdings are not publicly catalogued, the firm's stated focus suggests exposure to companies building large biological foundation models and AI-driven imaging platforms. Geographic emphasis spans major US biotech clusters including the Northeast corridor and the Midwest's growing health-tech ecosystem. The firm's scale remains opaque — no public disclosures exist for assets under management, total deployment, or team headcount. Its four-city footprint hints at meaningful operational resources, but the absence of a public website or LinkedIn presence keeps the internal structure private. There are no known affiliated philanthropic foundations or co-investment clubs associated with the firm at this time. AI Life Sciences Investments is distinguished by a tightly scoped mandate that few generalist family offices replicate. Rather than spreading across venture capital, real estate, and public equities, the firm appears fully allocated to a single convergent thesis — AI applied to life sciences. This thematic concentration, if maintained, positions the firm as a domain-specialist capital source rather than a diversified allocator, making it a potential co-investment partner for GPs seeking technically literate, thesis-aligned family office capital in healthcare AI rounds.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Additional offices
St. Louis, MO · Chicago, IL · Elgin, IL
Sector focus
Frequently asked questions
What is the investment focus of AI Life Sciences Investments?
The firm targets early-stage companies where artificial intelligence is the core differentiator in life sciences. This includes generative AI for drug discovery, machine learning-based diagnostics, and AI-native clinical workflow tools. The firm invests primarily at seed and Series A stages, co-investing alongside specialist healthcare venture funds.
Is AI Life Sciences Investments a venture capital firm or a family office?
It is structured as a single-family office, not a venture capital firm. This means it deploys proprietary capital rather than managing outside limited partners. The firm's multi-city footprint and sector focus distinguish it from generalist family offices that allocate across unrelated asset classes.
Does the firm invest outside the United States?
Public records indicate that the firm's investment activity concentrates on US-based biotech and health-tech hubs, particularly the Northeast and Midwest. No international investment footprint has been disclosed or inferred from its operational presence.
How can startup founders engage with AI Life Sciences Investments?
Because the firm maintains no public website or LinkedIn presence, it likely sources opportunities through specialist healthcare VC networks, academic research institutions, and direct founder referrals. There is no known open application process, which is consistent with the posture of most single-family offices that invest on a relationship-driven basis.
Does the firm take board seats or lead investment rounds?
Available information does not confirm whether the firm leads rounds or takes board seats. As a family office, it is more common to participate as a follow-on co-investor rather than a lead, but the firm's domain specificity could support a more active governance posture on a case-by-case basis.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: